Elevance Health stock: CMS lawsuit puts $516 million at stake
Published on 11/13/2026 at 17:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSWhat matters for investors
- Elevance challenges the calculation of its 2027 Medicare Advantage star ratings in federal court.
- The complaint targets 11 measures used across 12 contracts and seeks a recalculation for future payments.
- The case remains unresolved, leaving the potential financial effect dependent on court and CMS action.
Elevance Health filed a complaint on November 6, 2026, against the Centers for Medicare & Medicaid Services and the Department of Health and Human Services over the calculation of its 2027 Medicare Advantage star ratings. Insurance Business reported on November 10 that the insurer alleges CMS used 11 measures that were not adopted through the formal rulemaking process required for standards tied to Medicare payments.
The complaint covers 12 Elevance contracts serving members in several states and Puerto Rico, as well as a national contract. Elevance says removing the disputed measures would raise every affected contract's rating by at least half a star, potentially changing eligibility for quality bonus payments and the share of plan rebates retained by insurers.
Legal case targets rating methodology
Two of the challenged measures concern medication adherence and use Part D prescription drug event data, according to the complaint as described by Insurance Business. Elevance argues that the data falls outside the sources permitted for Medicare Advantage star ratings.
The insurer also points to a May 2026 federal court ruling involving Clover Insurance. Elevance says CMS removed the same defective measures from Clover's 2027 ratings while retaining them in Elevance's published calculations. The company is asking the court to invalidate the affected ratings, require a new calculation and use the revised results for 2028 payments and rebates.
The allegations have not been tested on the merits, and no court ruling has determined whether CMS acted unlawfully. Further filings, early court decisions and future CMS action will shape the financial relevance of the case.
Current trading context
Elevance Health stock traded at 384.65 euros on Lang & Schwarz at 17:01 CET on Friday, November 13. The quote provides a current trading reference as investors assess the potential effect of the litigation on the insurer's Medicare Advantage business.
Elevance Health at a glance
- Company: Elevance Health
- ISIN: US0367521038
- Ticker: ELV
- Trading venue: Lang & Schwarz
- Quote: 384.65 euros at 17:01 CET on Friday, November 13, 2026
- Legal filing: November 6, 2026
- Disputed contracts: 12 Medicare Advantage contracts
US equities remain in focus through current market reports.
Further legal filings, court decisions and CMS action will determine whether the rating dispute affects Elevance's future payment position. More news and analyses on Elevance Health stock.
